Mobile community UTI testing arrives in Glasgow in 2026
Quick and accurate UTI diagnostics make for better clinical decisions
New webinar: A real-world performance study of the Lodestar UTI testing system
New study data demonstrates Lodestar more accurate than lab culture
Crowdcube fund now open! Invest directly into Llusern today
Barclays Entrepreneur of the Year and Beyond Biotech podcast
New antibiogram data shows Lodestar covers 96% of UTI pathogens
A perfect partnership at The Forbury Clinic
Llusern Scientific Announces Key Appointments to Strengthen its Executive Team
Lodestar DX helps reduce antibiotic use at elderly care home
Llusern Scientific announces ISO 13485 certification
Llusern grabs the limelight at Arab Health 2025
Study shows Lodestar DX accurately identifies uropathogens in mixed growth cultures
Llusern kicks off Series A round at BioSeed 2025
David Browning appointed as Chairman of Llusern Scientific
Llusern secures Seed Investment from DBW
Llusern’s Lodestar DX Evaluation Published in JAC-AMR: Demonstrating High Correlation with Gold Standard UTI Testing
Longitude Prize on AMR
Bio 2024, San Diego
Two abstracts published by JAC-AMR
Poster presentations at BSAC UTI conference
Llusern at ECCMID23 in Copenhagen
Women feel ‘failed’ by UTI testing system – ITV News
Llusern included in NICE early value assessment for UTI testing
Llusern win at MediWales Awards 2022
Radio 4’s Woman’s Hour talk UTIs with Llusern
Llusern wins at the Wales STEM Awards
UTI test undergoing clinical verification and validation
